Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38 alpha inhibitors

Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543-4000, USA.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.33). 05/2008; 18(8):2652-7. DOI: 10.1016/j.bmcl.2008.03.019
Source: PubMed

ABSTRACT The synthesis and structure-activity relationships (SAR) of p38 alpha MAP kinase inhibitors based on a pyrazolo-pyrimidine scaffold are described. These studies led to the identification of compound 2x as a potent and selective inhibitor of p38 alpha MAP kinase with excellent cellular potency toward the inhibition of TNFalpha production. Compound 2x was highly efficacious in vivo in inhibiting TNFalpha production in an acute murine model of TNFalpha production. X-ray co-crystallography of a pyrazolo-pyrimidine analog 2b bound to unphosphorylated p38 alpha is also disclosed.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant kinase signaling leads to a multitude of disease states. The clinical and commercial success of agents typified by imatinib or dasatinib in the treatment of hematological malignancies has further validated kinase inhibition as a useful clinical strategy. This increased interest in kinases as therapeutic targets is evidenced by the rapidly increasing number of patent applications and peer-reviewed articles. This article discusses recent Patent that describe small molecules targeting the DFG-in active kinase conformation, by the so-called 'Type I½' inhibitor, against a small set of clinically relevant targets such as B-Raf, p38α, Jak2 and EphB4. Preclinical and clinical data are also highlighted for the most promising new molecular entities.
    Future medicinal chemistry 03/2011; 3(3):309-37. DOI:10.4155/fmc.10.294 · 4.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The p38 mitogen-activated protein (MAP) kinase plays a central role in inflammation. It has been the subject of extensive efforts in both basic research and drug discovery for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where aberrant cytokine signaling is the driver of the disease. This article reviews the patent and journal publication activities during 2006-2008 describing novel small molecule p38 alpha inhibitors.
    Current Topics in Medicinal Chemistry 11/2008; 8(16):1452-1467. DOI:10.2174/156802608786264245 · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Continuous synthesis of N-methylhomopiperazine over Cu–Cr–Mg/γ-Al2O3 has been developed. The doped Cr improves the dispersion of the Cu0 particles and inhibits the generation of CuAl2O4 so that the Cu0 particles are retained as the active sites. Doped Mg neutralizes the strong acid sites in Cu20Cr10Mg10/γ-Al2O3, and led to a decrease in coking side reactions. The reaction parameters were optimized and N-methylhomopiperazine was obtained in a yield of 66%. Graphical Abstract A continuous process for the preparation of N-methylhomopiperazine and homopiperazine has been developed. The cyclization of N-β-hydroxyethyl-N-methyl-1,3-propanediamine and N-β-hydroxyethyl-N-1,3-propanediamine proceeded effectively over a Cu20Cr10Mg10/γ-Al2O3 catalyst in a fixed-bed reactor.
    Catalysis Letters 08/2011; 141(8):1142-1148. DOI:10.1007/s10562-011-0591-5 · 2.29 Impact Factor